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Monosomal karyotype (MK) and complex karyotype (CK) are well known to be associated with a very poor
clinical outcome in patients with acute myeloid leukemia (AML). However, whether or not the prognostic
impact of MK and CK remains relevant for patients who have undergone allogeneic hematopoietic cell
transplantation (allo-HCT) is still unclear. We retrospectively analyzed the status of MK and CK, as well as
other clinical laboratory features, in 148 allo-HCT AML patients at our institution and correlated with their
event-free survival (EFS) and overall survival (OS) after transplantation. MK and CK were identiﬁed in 14 (9%)
and 19 (13%) cases, respectively. On univariate analysis, only age (60 years) and WBC count (15  109/L)
were signiﬁcant adverse predictors for EFS (P < .001 and P ¼ .017, respectively) and OS (P ¼ .002 and P ¼ .021,
respectively). MK, CK, and other relevant parameters analyzed did not affect the clinical outcome. Multi-
variable analysis conﬁrmed that both older age and high WBC count were independent prognostic factors for
a shorter OS (P ¼ .001 and P ¼ .003, respectively) and a shorter EFS (P < .001 and P ¼ .001, respectively). Our
results indicate that neither MK nor CK are high-risk factors in AML patients undergoing allo-HCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION However, the research around prognostic factors for AML
Currently, many prognostic factors have been identiﬁed
for acute myeloid leukemia (AML), a hematological malig-
nancy of myeloid stem cells with heterogeneous biology and
clinical outcomes. Cytogenetic information has been shown
to have high prognostic strength in a patient’s response to
therapy, their risk of relapse, and their overall survival (OS)
[1-4]. Various methods of stratifying cytogenetic risk have
been proposed by groups such as the Medical Research
Council (MRC), Southwest Oncology Group/Eastern Cooper-
ative Oncology Group, Cancer and Leukemia Group B, and
Dana-Farber Cancer Institute [1-4]. In all these risk stratiﬁ-
cations there has been a consensus that complex karyotype
(CK, deﬁned as 4 autosomal structural abnormalities by
revised MRC criteria or as 3 autosomal structural abnor-
malities by Southwest Oncology Group criteria) results in a
poor prognosis [1-4]. Age and WBC count have also long
been shown to have prognostic value in AML as well [5-9].
Monosomal karyotype (MK, deﬁned as 2 autosomal
monosomies or 1 autosomal monosomy with other struc-
tural abnormalities) has more recently been shown to be a
very strong predictor, stronger than both cytogenetic risk
and CK [8,10-14]. Certain immunophenotypic markers, such
as CD7, CD11b, CD15, CD34, CD56, and CD117, have also been
found to be prognostic in AML [15-28].edgments on page 694.
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plantation (allo-HCT) is not nearly as extensive. Prognostic
factors determined for transplant patients include bone
marrow status, donor relatedness, source of stem cells, time
between diagnosis and allo-HCT, remission status at time of
allo-HCT, and cytogenetic risk, including CK and MK
[11,29,30]. Whether or not MK and CK remain signiﬁcant
after allo-HCT is still debatable, with different centers ﬁnding
contrasting trends [7,31,32]. Herewe investigatedwhether or
not MK and CK (following revised MRC criteria) were nega-
tive risk factors for AML patients undergoing allo-HCT. In
addition, we evaluated the prognostic impact of various
clinical laboratory features including patient age, sex, WBC
count, cytogenetic risk, and presence of immunophenotypic
markers CD7, CD11b, CD15, CD34, CD56, and CD117, while
adjusting for time between diagnosis and allo-HCT, remis-
sion status at time of allo-HCT, and donor relatedness.
METHODS
Our retrospective study included adult AML patients at the University
Health Network, Toronto, Ontario, Canada. The study was approved by the
Research Ethics Board of theUniversityHealthNetwork. Fromour pool of 1740
AML patients, who were ﬁrst registered at the University Health Network
between January 2005 and December 2012, 230 patients received allo-HCT, of
which 148 had available cytogenetic information. These 148 transplant
patients received their allo-HCT between December 2005 and January 2013.
The median time from diagnosis to transplantation was 9.1 months. Patients
were stratiﬁed by cytogenetic risk based on revised MRC guidelines [1].
Patients with acute promyelocytic leukemia were included and placed
under low cytogenetic risk. Patients younger than age 60 years received
myeloablative conditioning regimens (cyclophosphamide-total body irradia-
tion [TBI], busulfan-cyclophosphamide, cytarabineþcyclophosphamideþTBI,
or ﬂudarabineþ4 day dose of busulfan þ/ low-dose TBI), whereas patients
older than age 60 received nonmyeloablative conditioning regimens (ﬂudar-
abineþlow-dose TBI, ﬂudarabineþ2-day dose of busulfan þ/ low-dose TBI).
Transplantation.
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remission (CR2) were transplanted according to the program policy.
Our non-transplant control group consisted of 200 age-matched adult
AML patients at the same center who did not receive allo-HCT. Furthermore,
the control group was selected only from patients who had survived at least
6 months to account for the fact that every patient in our transplant group
had to survive a certain amount of time before they could receive allo-HCT.
The choice of 6 months was based on the median time from diagnosis to
transplantation for our MK patients. Six months after diagnosis was used as
a reference point for the non-transplant group and the date of allo-HCT as
our start point for transplant patients.
Karyotype Analysis
Karyotypes were obtained from diagnostic bone marrow samples with
standard methods and in accordance with International System for Human
Cytogenetic Nomenclature guidelines [33]. A minimum of 20 metaphases
were required to have been examined to rule out the presence of clonal
chromosomal abnormalities.
Immunophenotypic Analysis
To perform immunophenotypic analysis, bone marrow or peripheral
blood samples were prepared and processed using a whole blood lysis
technique, followed by multiparameter ﬂow cytometry (FC 500 Flow Cy-
tometer, Beckman Coulter, Miami, FL). Leukemic blasts were selected based
on the dim CD45 presence against low side scatter and then analyzed with
various combinations of 4 to 5 conjugated antibodies along with an auto-
ﬂuorescent negative control [16]. Only samples that contained 20% or more
blasts and 10,000 list mode events recorded at the blast gate were used in
the analysis; presence of an antigen was considered positive if it was
expressed on at least 20% of the blasts in the sample.
Statistical Analysis
Categorical variables such as gender, age over 60, WBC count> 15109/
L, cytogenetic risk, CK, MK, time between diagnosis and allo-HCT over 18
months, remission status at time of allo-HCT, donor relatedness, CD7, CD11b,
CD115, CD34, CD56, and CD117 were summarized with counts andTable 1
Univariate Analysis and 4-Year Survival for OS and EFS for the Allo-HCT Population
Characteristic Subcategory All Patients n (%)
Age <60 yr 108 (73)
60 yr 40 (27)
Sex Male 78 (53)
Female 70 (47)
WBC count <15  109/L 87 (59)
15  109/L 61 (41)
Cytogenetic risk Favorable 12 (8)
Intermediate 110 (74)
Unfavorable 26 (18)
CK e 137 (93)
þ 11 (7)
MK e 134 (91)
þ 14 (9)
Time between diagnosis and HCT <18 mo 122 (82)
18 mo 26 (18)
Status at transplantation CR1 113 (76)
CR2 35 (24)
Donor Related 74 (50)
Unrelated 74 (50)
CD7 e 94 (64)
þ 33 (22)
CD11b e 55 (37)
þ 70 (47)
CD15 e 53 (36)
þ 73 (49)
CD34 e 45 (30)
þ 79 (53)
CD56 e 97 (66)
þ 18 (12)
CD117 e 37 (25)
þ 81 (55)
Values in bold indicate P < .20. CD indicates cluster of differentiation.
* Univariate signiﬁcance.percentages. Continuous variables, such as follow-up duration, time to
relapse, and patient age, were summarized with medians and ranges as
necessary. Follow-up durationwas based on the last follow-up, starting from
the date of allo-HCT. Time to relapse was calculated up to date of relapse,
starting from the date of allo-HCT. Patient age was calculated for the age of
the patient on the date of their allo-HCT. Endpoints for our non-transplant
control group used a date 6 months after diagnosis as a reference point in
place of date of transplant.
OS and event-free survival (EFS) were calculated using the Kaplan-Meier
product-limit method. Log-rank test was used as a univariate analysis to
compare levels of the potential predictive factors. Cox proportional hazards
regressionwas used to assess the joint effect of predictors on OS and EFS that
were found to be a potential predictor at the univariate level and/or that are
clinically important. A covariate was considered as a potential predictor if
the univariate analysis produced P .20 [34]. Variables considered clinically
important for this study were WBC count, cytogenetic risk, CK, MK, time
between diagnosis and allo-HCT over 18 months, patient status at trans-
plant, and donor relatedness. Results were considered signiﬁcant if P < .05.
Potential predictors from the univariate were put through a backward
stepwise Wald Cox proportional hazards regression until remaining cova-
riates had P < .10, after which another Cox proportional hazards regression
was done with the signiﬁcant covariates (P < .05) from the backward
stepwise Wald analysis, along with the clinically important variables. All P
values were 2-sided and pertained to the event hazard ratio rather than
comparing survival percentages at given times. Statistical analyses were
performed using SPSS v20 (IBM; Armonk, NY).RESULTS
Patient Characteristics
Patient characteristics and statistical results for the 148
patients in the transplant population group are summarized
in Table 1. The median age of the patients at time of trans-
plantation was 51.9 years (range, 24.2 to 70.9). Of the 148
patients, 12 (8%) were good risk, 110 (74%) were intermediate(N ¼ 148)
<TSH>OS <TSH>EFS
4-Year Survival (%) Log Rank 4-Year Survival (%) Log Rank
P P
53 .002* 49 < .001*
25 20
41 .243 36 .249
49 46
51 .021* 47 .017*
36 33
43 .921 43 .856
46 41
41 36
45 .642 42 .324
37 26
46 .436 42 .182
36 28
47 .105 43 .084
33 29
47 .292 44 .178
36 30
47 .314 43 .277
42 38
41 .199 37 .150
53 53
45 .479 45 .321
43 38
38 .978 36 .890
44 41
47 .512 42 .666
41 38
42 .664 40 .829
38 38
46 .989 38 .696
41 41
Table 2
Population Characteristics for Control Non-Transplant Population (N ¼ 200)
Characteristic Subcategory All Patients n (%)
Age <60 yr 141 (70)
60 yr 59 (30)
Sex Male 108 (54)
Female 92 (46)
WBC count <15  109/L 123 (62)
15  109/L 77 (38)
Cytogenetic risk Favorable 33 (16)
Intermediate 135 (68)
Unfavorable 32 (16)
CK e 182 (91)
þ 18 (9)
MK e 183 (92)
þ 17 (8)
CD7 e 113 (56)
þ 52 (26)
CD11b e 76 (38)
þ 95 (48)
CD15 e 68 (34)
þ 98 (49)
CD34 e 57 (28)
þ 110 (55)
CD56 e 136 (68)
þ 26 (13)
CD117 e 64 (32)
þ 85 (42)
CD indicates cluster of differentiation.
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CKþ and 14 were MKþ, of which 9 were CKþMKþ. All MK
patients were in the poor-risk category. The median time
from diagnosis to transplantation was 9.1 months; for MK
patients, themedian timewas 6.0 months. Themedian age of
MK patients at time of transplantationwas 52.0 years (range,
25.0 to 66.7), and the median age of CK patients at time of
transplantation was 52.4 years (range, 41.6 to 64.6). The
median duration of CR1 for patients transplanted in CR2 was
8.8 months (range, 1.4 to 42.3). The median OS and EFS of the
transplant patients were 33.6 months and 27.6 months,
respectively.
Patient characteristics for the 200 participants in the
control group are summarized in Table 2. Because the control
group was age matched, the median age of patients at
reference timewas 51.9 years (range, 23.8 to 71.7). Of the 200
patients, 33 (16%) were good risk, 135 (68%) were interme-
diate risk, and 32 (16%) were poor risk. Of the poor risk, 18
were CKþ and 17 were MKþ, of which 12 were CKþMKþ.
One MK patient was in the intermediate-risk category,
whereas the remainder were in the poor-risk category. The
median age of MK patients at reference time was 58.6 years
(range, 32.8 to 71.3 years), and the median age of CK patients
at reference time was 59.9 years (range, 30.2 to 71.3 years).
The median OS and EFS of the non-transplant control group
were 24.8 months and 15.0 months, respectively.
Univariate Analysis
Old age (60 years) was signiﬁcantly associated with
poor EFS and OS (median EFS of 12.1 months versus 52.9
months, P < .001; median OS of 15.7 months versus median
OS not reached, P ¼ .002) in our transplant population.
Furthermore, high WBC count (15  109/L) was also asso-
ciated with shorter EFS and OS (median EFS of 12.1 months
versus 43.2 months, P ¼ .017; median OS of 12.8 months
versus 47.8 months, P ¼ .021). MK was not signiﬁcantly
correlated with either EFS (P ¼ .182) or OS (P ¼ .436). CK was
also not signiﬁcantly correlated with EFS (P¼ .324) or OS (P¼
.642). For transplant-related variables, time between diag-
nosis and allo-HCT was insigniﬁcant for both EFS and OS (P¼
.084 and P ¼ .105, respectively), as was remission status (CR1
and CR2) at time of transplant (P ¼ .178 and P ¼ .292,
respectively) and donor relatedness (P ¼ .277 and P ¼ .314,
respectively). There was also no signiﬁcant association with
the other variables: sex, cytogenetic risk, or any immuno-
phenotypic markers analyzed.
In our non-transplant control group, old age (60 years)
was also a signiﬁcant predictor of both shorter EFS and OS
(P ¼ .001 for both). However, high WBC count (15  109/L)
was insigniﬁcant for both EFS and OS (P ¼ .727 and P ¼ .540,
respectively). CK was correlated with a poor OS and EFS (P <
.001 for both). MK was also a signiﬁcant predictor for a
shorter EFS and OS (P < .001 for both). In addition, Student’s
t-test was conducted and found that for CK and MK patients,
age was not statistically different between the control and
transplant populations (P ¼ .556, and P ¼ .328, respectively).
OS Kaplan-Meier curves for age, WBC count, MK, and CK for
both our transplantation population and non-transplant
control group are shown in Figure 1.
Multivariable Analysis
The backward stepwise Wald Cox regression for OS
identiﬁed both old age and high WBC count as signiﬁcant
variables (P ¼ .001 and P ¼ .011), and the backward stepwise
Wald Cox regression for EFS also identiﬁed both old age andhigh WBC count as signiﬁcant variables (P < .001 and P ¼
.002, respectively) in our transplant population. The second
Cox regressions combined old age and high WBC count with
other clinically signiﬁcant variables (MK, CK, cytogenetic
risk, time between diagnosis and allo-HCT over 18 months,
remission status at transplant, and donor relatedness;
Table 3) and revealed that old age was an independent pre-
dictor of worse EFS and OS (P < .001 and P ¼ .001, respec-
tively). High WBC count was also an independent predictor
of shorter EFS and OS (P ¼ .003 and P ¼ .006, respectively).
MK, CK, cytogenetic risk, time between diagnosis and allo-
HCT, remission status at time of transplantation, and donor
relatedness did not signiﬁcantly affect clinical outcomes in
our transplant population.
DISCUSSION
MK and other cytogenetic factors have been considered as
the most important prognostic factors for AML [1-5,8,10-14],
so it is interesting that MK, CK, and cytogenetic risk were all
statistically insigniﬁcant in our allo-HCT cohort. Our results
differ from those by Oran et al. [31], who found MK to be the
strongest cytogenetic risk factor for relapse incidence,
progression-free survival, and OS in patients receiving allo-
HCT (allo-HCT N ¼ 212). However, our results do align with
Stelljes et al. [32], who also found age to be signiﬁcant and
MK to be insigniﬁcant for OS (P ¼ .849) for allo-HCT patients
(allo-HCT N ¼ 55). Fang et al. [11] demonstrated that allo-
HCT could partially overcome the negative prognosis of MK
for younger patients (<60; n ¼ 341) but not for their older
population (n ¼ 91). We found that MK was insigniﬁcant for
patients both older than and younger than age 60 for OS and
EFS. However, our older age group only had 5 MKþ patients,
only 3 of which had died; thus, future studies with larger
population sizes would be required to conﬁrm our results.
Furthermore, Fang et al. [11] identiﬁed that MKþ/CKþ
together was a stronger predictor than MKþ or CKþ indi-
vidually for transplant patients. We found that MKþ/CKþ
patients trended toward a worse OS (median OS of 15.0
months versus 34.0 months) and EFS (median EFS of 14.0
Figure 1. OS Kaplan-Meier curves for age ([A] allo-HCT P ¼ .002, [B] control P ¼ .001), WBC count ([C] allo-HCT P ¼ .021, [D] control P ¼ .540), MK ([E] allo-HCT
P ¼ .436, [F] control P < .001), and CK ([G] allo-HCT P ¼ .642, [H] control P < .001).
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signiﬁcance (P¼ .669 and P¼ .287, respectively). This may be
due to the smaller sample size in our cohort. In contrast, in
our non-transplant control group, MKþ/CKþ conferred a
shorter OS and EFS (P < .001 for both).
Increasing age has long been known to negatively inﬂu-
ence survival in AML in general [6], and other studies have
further shown this to be true in transplant patients as well:
Stelljes et al. [32] showed that age older or younger than 40
years was the only signiﬁcant predictor of OS for their pa-
tientswho received allo-HCT (P¼ .032). However, it should be
noted that Stelljes et al. studied cytogenetically high-risk
patients and their transplant group received allo-HCT in
CR1 only, whereas we evaluated all allo-HCT AML patients,
regardless in which complete remission the transplantationTable 3
Multivariable Analysis for OS and EFS for the Allo-HCT Population (N ¼ 148)
Trait Subcategory OS
Hazard Ratio
Age <60 yr 1.000
60 yr 2.525 (1.495
WBC count <15  109/L 1.000
15  109/L 2.049 (1.225
MK MKe 1.000
MKþ 1.337 (.389-4
CK CKe 1.000
CKþ 1.259 (.375-4
Cytogenetic risk Intermediate 1.000
Favorable .776 (.216-2
Unfavorable 1.007 (.379-2
Time between diagnosis and BMT <18 mo 1.000
18 mo 1.610 (.775-3
Status at transplantation CR1 1.000
CR2 1.060 (.543-2
Donor Related 1.000
Unrelated 1.247 (.740-2
Values in bold indicate P < .05. CI indicates conﬁdence interval.
* Univariate signiﬁcance.was performed. Jourdan et al. [35] also found older age (33
years) to have prognostic power for OS (P ¼ .04, allo-HCT N ¼
105). Few studies have shown age to be insigniﬁcant in
transplant patients, such as the study by Bashir et al. [36] in
which they found age older or younger than 55 years to be
insigniﬁcant for both OS and EFS (P ¼ .811 and P ¼ .478,
respectively; allo-HCT N ¼ 44). Their study differs from ours
in that they only looked at unrelated donors and that, at their
center, they only performed transplantations in patients
younger than 65, whereas we considered both patients with
related and unrelated donors and our center had no upper
age limit for transplantation. The fact that our center uses
nonmyeloablative conditioning regimens in patients age 60
years or older may also factor into the result of 60 years of age
being a signiﬁcant cut-off for older age. However, we also ranEFS
(95% CI) P Hazard Ratio (95% CI) P
1.000
-4.274) .001* 2.755 (1.653-4.587) < .001*
1.000
-3.425) .006* 2.165 (1.309-3.584) .003*
1.000
.587) .645 1.464 (.453-4.739) .524
1.000
.237) .709 1.605 (.512-5.025) .416
1.000
.778) .697 .822 (.226-2.994) .767
.678) .988 1.072 (.398-2.885) .891
1.000
.344) .201 1.600 (.794-3.226) .188
1.000
.070) .862 1.174 (.618-2.227) .624
1.000
.101) .408 1.293 (.774-2.159) .327
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and still found age to be a signiﬁcant predictor (P ¼ .026).
WBC count at diagnosis has been shown to be a signiﬁ-
cant predictor of OS and EFS in AML in general [5,6], but its
strength as a predictor speciﬁcally in allo-HCT patients is not
well documented. The only study investigating the effect of
WBC count in adult allo-HCT patients was done by Jourdan
et al. [35], who found that WBC count above or below 30 
109/L was not signiﬁcant for OS (P ¼ .46) nor for leukemia-
free survival (P ¼ .61). The population used by Jourdan
et al. had amedian age of 33 years and patients received their
allo-HCT between 1984 and 1992, whereas our population
has a median age of 51.9 years and patients received their
allo-HCT between 2005 and 2012.
Expressions of CD7 [17,18], CD11b [15,19-21], CD34
[16,22-24], CD56 [16,25], and CD117 (also known as KIT) [26]
antigens have been associatedwith an unfavorable prognosis
in AML patients, whereas expression of CD15 has been
associated with a favorable prognosis [21,27,28]. Although
CD56 has been linked to a negative prognostic factor for
transplant patients, none of the other immunophenotypic
markers we evaluated has been studied for their prognostic
signiﬁcance in allo-HCT AML patients. Yang et al. [37] found
CD56 to be a negative prognostic factor for allo-HSCT AML
patients with t(8;21) for disease-free survival (P ¼ .02; allo-
HCT N ¼ 15). Our population only had 7 allo-HCT patients
with t(8;21), 4 of which were CD56þ; those patients did not
reach a median EFS, whereas patients with t(8;21)/CD56e
had a median EFS of 1.8 months (P ¼ .300). A larger cohort is
needed to conﬁrm these results. All the immunophenotypic
markers we investigated did not affect the clinical outcomes
of our allo-HCT AML patients.
In conclusion, old age and high WBC count were the only
2 signiﬁcant adverse factors for OS and EFS in our population
of allo-HCT AML patients, and cytogenetic factors, immuno-
phenotypic markers, and transplant-speciﬁc variables were
not signiﬁcant predictors. Our results suggest that allo-HCT
may overcome the negative prognostic impact of MK and
CK, and future prospective clinical trials with larger size co-
horts need to be done to conﬁrm these results.ACKNOWLEDGMENTS
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